United Therapeutics Corporation financials

  1. Home
  2. Financials
  3. UTHR
UTHR CIK 0001082554

Source: EDGAR filings · Built 2026-06-02T04:17:54Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 1.04B 1.08B 747.60M 663.70M 477.40M 696.40M
EBITDA 1.58B 1.45B 1.24B 1.03B 605.80M 643.50M
Working Capital 3.14B 3.14B 2.75B 3.04B 2.02B 1.84B
Gross Margin 87.92% 89.24% 88.94% 92.17% 92.73% 92.71%
Operating Margin 46.89% 47.86% 50.91% 50.60% 32.98% 40.02%
Net Margin 41.94% 41.53% 42.31% 37.56% 28.23% 34.71%
Return on Equity (ROE) 18.81% 18.55% 16.45% 15.16% 12.02% 15.16%
Return on Assets (ROA) 16.94% 16.23% 13.74% 12.03% 9.20% 11.15%
Current Ratio 6.60× 5.25× 4.41× 9.85× 7.61× 6.70×
Effective Tax Rate 22.13% 22.35% 22.72% 23.49% 19.89% 19.42%
Cash Conversion Ratio 1.17× 1.11× 0.99× 1.10× 1.26× 1.47×
Accruals Ratio -0.03× -0.02× 0.00× -0.01× -0.02× -0.05×
SBC % of Revenue 4.64% 5.00% 1.68% 5.52% 8.22% 11.04%
CapEx Coverage 3.00× 5.38× 4.24× 5.78× 4.95× 12.74×
Free Cash Flow Per Share $21.73 $22.28 $15.04 $13.68 $10.09 $15.61

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 17.49× 14.32× 11.10× 18.54× 21.48× 13.15×
P/FCF 22.43× 15.84× 14.62× 20.32× 21.41× 9.72×
FCF Yield 4.46% 6.31% 6.84% 4.92% 4.67% 10.29%
EV / EBITDA 12.49× 9.74× 7.38× 11.48× 14.61× 9.35×
P/S 6.68× 5.50× 4.44× 6.61× 5.78× 4.55×
P/B 3.00× 2.45× 1.73× 2.67× 2.46× 1.99×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 3.18B 2.88B 2.33B 1.94B 1.69B 1.48B
Revenues — — — — — 1.48B
Cost of Goods and Services Sold 384.40M 309.70M 257.50M 151.60M 122.50M 108.10M
Gross Profit 2.80B 2.57B 2.07B 1.78B 1.56B 1.38B
Research and Development Expense 550.00M 481.00M 408.00M 322.90M 540.10M 357.70M
Selling, General and Administrative Expense 755.80M 709.70M 477.10M 482.10M 467.00M —
Operating Income (Loss) 1.49B 1.38B 1.18B 979.70M 555.90M 593.60M
Income Tax Expense (Benefit) 379.20M 343.90M 289.50M 223.30M 118.10M 124.10M
Net Income (Loss) Attributable to Parent 1.33B 1.20B 984.80M 727.30M 475.80M —
Earnings Per Share, Basic $30.13 $26.44 $21.04 $15.98 $10.60 $11.65
Weighted Average Number of Shares Outstanding, Basic 44.30M 45.20M 46.80M 45.50M 44.90M 44.20M
Earnings Per Share, Diluted $27.86 $24.64 $19.81 $15.00 $10.06 $11.54
Weighted Average Number of Shares Outstanding, Diluted 47.90M 48.50M 49.70M 48.50M 47.30M 44.60M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 1.56B 1.70B 1.21B 961.20M 894.80M 738.70M
Assets, Current 3.70B 3.87B 3.55B 3.38B 2.32B 2.17B
Assets 7.88B 7.36B 7.17B 6.04B 5.17B 4.62B
Liabilities, Current 560.60M 738.10M 804.40M 343.20M 305.40M 323.30M
Liabilities 783.80M 920.00M 1.18B 1.25B 1.21B 1.22B
Stockholders' Equity Attributable to Parent 7.10B 6.44B 5.98B 4.80B 3.96B 3.40B
Common Stock, Shares, Outstanding 43.64M 44.83M 47.04M 46.03M 45.11M 44.51M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 1.56B 1.33B 978.00M 802.50M 598.20M 755.70M
Payments to Acquire Property, Plant, and Equipment 520.50M 246.50M 230.40M 138.80M 120.80M 59.30M
Net Cash Provided by (Used in) Investing Activities -551.30M 417.20M -719.60M -811.50M -486.90M -738.50M
Payments for Repurchase of Common Stock 1.00B 1.00B 0 0 — —
Net Cash Provided by (Used in) Financing Activities -1.15B -1.25B -11.90M 75.40M 44.80M -16.90M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (UTHR CIK 0001082554), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

XOS

XOS, INC.

EVH

Evolent Health, Inc.

OFG

OFG Bancorp